Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
Document Type
Journal Article
Publication Date
6-3-2020
Journal
Cardiovascular Diabetology
Volume
19
Issue
1
Inclusive Pages
72
DOI
10.1186/s12933-020-01046-z
APA Citation
Awal, H. B., Nandula, S. R., Domingues, C. C., Dore, F. J., Kundu, N., Brichacek, B., Fakhri, M., Elzarki, A., Ahmadi, N., Safai, S., Fosso, M., Amdur, R. L., & Sen, S. (2020). Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.. Cardiovascular Diabetology, 19 (1). http://dx.doi.org/10.1186/s12933-020-01046-z
Peer Reviewed
1
Open Access
1
